| __timestamp | Mesoblast Limited | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 25434000 | 22622695 |
| Thursday, January 1, 2015 | 23783000 | 24863028 |
| Friday, January 1, 2016 | 29763000 | 21351001 |
| Sunday, January 1, 2017 | 12065000 | 53837297 |
| Monday, January 1, 2018 | 5508000 | 16080096 |
| Tuesday, January 1, 2019 | 75173000 | 18525736 |
| Wednesday, January 1, 2020 | 81497000 | 2024000 |
| Friday, January 1, 2021 | 85731000 | 2548000 |
| Saturday, January 1, 2022 | 63572000 | 61556000 |
| Sunday, January 1, 2023 | 54922000 | 188157000 |
| Monday, January 1, 2024 | 41070000 |
Cracking the code
In the dynamic world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. Over the past decade, Mesoblast Limited and Telix Pharmaceuticals Limited have shown intriguing trends in their cost structures. From 2014 to 2023, Mesoblast's cost of revenue fluctuated, peaking in 2021 with a 70% increase from its 2014 figures. Meanwhile, Telix Pharmaceuticals experienced a dramatic surge in 2023, with costs soaring by over 700% compared to 2014. This sharp rise highlights Telix's aggressive expansion and investment strategies. However, the absence of data for Telix in 2024 suggests a potential shift or reevaluation in their financial reporting. As these companies navigate the complexities of the biotech industry, their cost of revenue remains a key indicator of their operational strategies and market positioning.
Zoetis Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down GSK plc and Mesoblast Limited's Expenses
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Incyte Corporation and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Analyzing Cost of Revenue: Pharming Group N.V. and Telix Pharmaceuticals Limited
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Alkermes plc
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses
Analyzing Cost of Revenue: ACADIA Pharmaceuticals Inc. and Mesoblast Limited
Analyzing Cost of Revenue: Mesoblast Limited and Taro Pharmaceutical Industries Ltd.